A nanoparticle has been developed by the Russian State Research and Technical University to deliver antibiotics to the target of an infection, reducing the dose of antibiotics to 1/6 to 1/7 of the original dose, reducing the side effects of antibiotics and reducing the development of resistance to pathogens.
The study is in the Journal of Applied Materials Interfaces of the American Chemical Society.
It is well known that microbial resistance to antibiotics has developed over the years due to rising morbidity, new infections and overuse of antibiotics, and it takes about 20 years of clinical trials to develop a new antibiotic.
At present, drug therapy is still the main method of fighting infection.
One way to solve this problem is to develop antimicrobial nanomaterials.
This method can help overcome the resistance of pathogens without causing side effects to patients.
Medical researchers believe that the main advantages of the new drugs are that they can significantly reduce the dose of antibiotics, reduce the burden on the body and slow the development of microbial resistance.
Researchers at the Russian National Research and Technical University have found that a novel nanohybrid based on hexagonal boron nitride (H-BN) and silver particles has high bactericidal and antifungal activity and can be used to deliver antibiotics to infected lesions.
Hexagonal nanoparticles of 100 nanometres of boron nitride were obtained by chemical vapor deposition (CVD) and deposited on the nanoparticles by UV decomposition of silver nitrate, which filled the cavity with antibiotics, said Cristina Guz, an engineer in the University’s Laboratory of Inorganic Nanomaterials.
After taking the medication, the antibiotics gradually enter the body over a period of nine days.
She points out that the use of silver particles can have an added bactericidal effect.
For example, nanoparticles loaded with gentamicin were effective against 38 strains of E. coli, a number that rose to 47 when silver particles were attached to their surfaces.
In addition, nanoparticles can increase the load of carrying antibiotics while easily penetrating from the circulatory system into tissues and back, thus ensuring continuous delivery of drugs to the infected lesions.
Christina Guz says new nanohybrids could destroy bacterial and fungal populations with much less active material than antibiotics.
In some cases, the dosages vary by a factor of 6 or 7.
Gentamicin, for example, inhibited E. coli U-122 at a minimum concentration of 256 mg/L, while the same nanohybrid had a similar effect at 40 mg/L.
The new drug has passed laboratory tests on more than 50 bacterial and fungal cultures, and the team is continuing preclinical testing of the new nanohybrid.